News Hub | News Direct
Back

air+djibouti


Article thumbnail News Release

Plurilock Security announces new product PromptGuard to deal with rise of AI in the workplace

Plurilock Security Inc.

Plurilock Security CEO Ian L. Paterson joined Steve Darling from Proactive to announce the unveiling of its new product, PromptGuard. Currently in beta, PromptGuard is an AI safety SaaS (Software-as-a-Service) platform designed for business and government customers. It will be offered as part of the Plurilock AI platform, showcasing the company's commitment to generative AI safety. Paterson explained that PromptGuard was developed utilizing Plurilock's new CASB (Cloud Access Security Broker) technology for AI. The platform has been the subject of a US provisional patent filing on July 18th. PromptGuard is an AI-driven cloud access security broker that ensures the protection of sensitive data while supporting employee use of AI systems. It provides robust AI guardrails without impeding the use of AI. The platform combines mature data loss prevention technology with new, patent-pending Plurilock AI platform technology. This unique combination enables users to interact with generative AI without exposing sensitive data through user-generated AI prompts. With PromptGuard, Plurilock Security addresses the growing need for secure AI usage within organizations. By safeguarding sensitive data and facilitating the responsible use of generative AI, PromptGuard empowers businesses and government entities to leverage AI technology while maintaining data privacy and security. Plurilock Security continues to push the boundaries of AI safety, and PromptGuard represents their dedication to providing innovative solutions for their customers in the evolving landscape of AI and data protection. Contact Details Proactive Investors +1 347-449-0879 action@proactiveinvestors.com Company Website https://www.proactiveinvestors.ca/

July 21, 2023 12:37 PM Eastern Daylight Time

Video
Article thumbnail News Release

NVIDIA Inception Chooses BioSig AI For Innovation In Healthcare AI, An Industry That Is Projected To Reach $272.9 Billion By 2030

Benzinga

By Faith Ashmore, Benzinga BioSig Technologies, Inc. (NASDAQ: BSGM) is a groundbreaking medical technology company that specializes in providing precision and accuracy in visualizing intracardiac signals. Recently, their subsidiary, BioSig AI Sciences, Inc. (BAIS), was chosen to join NVIDIA Inception. This prestigious program is designed to partner with companies that are revolutionizing industries through advancements in AI and data sciences. By being a part of NVIDIA Inception, BioSig AI Sciences gains access to valuable resources during critical stages of product development, prototyping and deployment. This includes engineering guidance, technical training, hardware and software support, co-marketing opportunities and exposure to the NVIDIA investment community. Leveraging NVIDIA's (NASDAQ: NVDA) vast array of tools and frameworks, BioSig AI Sciences aims to advance the research and development of its AI medical device platform for the healthcare industry. Ken Londoner, Chairman, CEO and Founder of BioSig, expressed excitement in joining this exclusive group of AI-centric technology companies, sharing “We are thrilled to join an elite group of AI-centric technology companies leading the evolution of machine learning and artificial intelligence across industries. NVIDIA Inception will help advance BioSig’s role in identifying transformational applications of artificial intelligence opportunities in healthcare.” BioSig AI Sciences is currently training its AI platform using electrocardiogram (ECG) and intracardiac electrogram (IECG) data from BioSig's patented PURE EP™ Platform. BioSig reports that this platform has been utilized in over 3,500 procedures and has been featured in peer-reviewed clinical research. By incorporating various data modalities including time series, text, image, video, and other clinically relevant signals, BioSig AI Sciences aims to assist healthcare systems in developing and deploying a comprehensive AI model that can understand structured, semi-structured and unstructured medical data. BioSig’s platform is aligned with the growth of artificial intelligence in the healthcare industry. In 2022, the market for AI in healthcare was valued at around $9.6 billion. However, experts predict that this market will experience a remarkable surge and it is projected to reach $272.9 billion by the year 2030. This growth is expected to occur at an impressive compound annual growth rate (CAGR) of 51.9% during the forecast period. BioSig Technologies seems well-positioned to help revolutionize the treatment of cardiovascular arrhythmias. By working closely with renowned physicians, experts and healthcare leaders in the field of electrophysiology (EP), BioSig Technologies is dedicated to tackling some of the most crucial challenges in healthcare, which include saving time, reducing costs and ultimately saving lives. Its latest partnership with NVIDIA seems indicative of the company’s focus on growth. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

July 21, 2023 09:25 AM Eastern Daylight Time

Article thumbnail News Release

AI Detection Bypass Tool Created By PhD Scores '100% Human Written' On Originality Test

KISS PR Brand Story

In a significant development in the field of artificial intelligence, Bars Juhasz, a PhD holder and former CEO of recently acquired ChatterQuant, is unveiling Undetectable AI, the first AI detection remover tool capable of AI detectors as human, as demonstrated recently by passing as 100% human written text, according to a test using the Originality AI detector.  This groundbreaking AI detection remover tool is set to redefine the boundaries of AI content generation and detection. The tool has officially scored 100% human written scores according to tests ran on Originality.ai Undetectable AI leverages advanced machine learning technology to transform AI-generated content into human-sounding text that is undetectable by AI content detection systems. This sophisticated rewriting technology is groundbreaking development” says Chris Perry, CEO of UD, “We are innovating in the industry of AI writing, enabling the creation of unique content that is indistinguishable from human-written text. "Our tool is designed to bypass AI detection methods, but it's also about pushing the boundaries of what AI can do," said Juhasz. "It's not just about creating content. It's about understanding the nuances of language, the subtleties of human communication, and the complexities of our world." The implications of this technology are far-reaching and transformative. It has the potential to revolutionize the field of AI writing, enabling AI to create research papers, blog posts, or even novels that are indistinguishable from human-written content. Moreover, Undetectable AI could also serve as a powerful tool for multilingual plagiarism detection, a feat currently challenging for most AI detection systems. "AI is a tool, not a replacement for human creativity," says Bars Juhasz, CTO and developer of the software. Juhasz also states "Our goal is not to replace human writers but to enhance their capabilities. With our tool, writers can create more unique, engaging content without worrying about AI detection." Another huge advantage offered by Undetectable AI is the ability to both detect AI content, and bypass AI detectors. Essentially, the Undetectable website has an accurate AI-detector that checks for AI-content, against 8 of the most widely used AI-detectors, and tells you how the content is scored. The Undetectable AI content detector was named the best out of all the major detectors recently by Tech & Learning, due to its precise and comprehensive capabilities. Media Contact: Devan Leos - Director of Communications - Undetectable AI devanleos@undetectable.ai Phone: N/a Release ID: 681677

July 20, 2023 10:00 PM Eastern Daylight Time

Image
Article thumbnail News Release

UNOS Applauds House Action to Improve Air Transport of Donor Organs

United Network for Organ Sharing

Today, the U.S. House of Representatives approved its 2023 Federal Aviation Administration (FAA) reauthorization bill, which includes a provision aimed at improving safety and efficiency in the transportation of donor organs through the nation's commercial aviation system. Section 834 of H.R. 3934, the Securing Growth and Robust Leadership in American Aviation Act, requires the Secretary of the Department of Transportation (DOT), in consultation with the FAA Administrator, to convene a working group to develop best practices for the transportation of an organ in the cabin of an aircraft. Before the September 11 attacks, organs – primarily kidneys – were transported within a commercial flight’s cabin, under supervision of the aircrew. Packaged organs were placed in or near the cockpit just before departure and quickly retrieved after landing. The attacks prompted significant changes to airport protocols, including no longer allowing transplant professionals without an airplane ticket to accompany an organ through security. As a result, organs currently travel in the cargo hold. Action by the House promises to review and possibly reverse that long standing practice. “I applaud the actions taken by the House today. I offer my profound thanks to those working with us to make this change a reality, namely Rep. Bruce Westerman and Rep. Greg Stanton from the House Transportation and Infrastructure Committee, and their colleagues Rep. Tracey Mann, Rep. Dusty Johnson, and Rep. Beth Van Duyne,” said United Network for Organ Sharing (UNOS) CEO Maureen McBride, Ph.D. “Today’s news is the result of collaborative efforts on behalf of patients waiting for the gift of life, while also honoring generous donors and their families. There is more work to be done as we ensure this legislation is enacted, but this is a critical step.” While not a common occurrence, any logistical delays heighten the risk that an organ cannot be transplanted. The post-September 11 relegation of organs to the cargo hold created challenges navigating cargo hours and cargo lock-out times - the cut-off time for receiving shipments before the scheduled departure of an aircraft. Not all airlines accept cargo, so options are limited for transporting organs by air, especially to areas served by smaller, regional airports. ”Any organ not ultimately transplanted represents a profound loss, both for the selfless donor’s family and the patient waiting,” said Dianne LaPointe Rudow, ANP-BC, DNP, FAAN, President of UNOS. “Our donation and transplant community is called to honor the gift of life, and that commitment includes not only publicly identifying the issue, but seeking substantive solutions to address it. We owe our patients nothing less.” The provision included in the House version of the FAA reauthorization bill is the result of ongoing advocacy by UNOS, Organ Procurement Organizations (OPOs) and other members of the nation’s organ donation and transplant community. Since December of 2022, UNOS has engaged with the FAA leadership, the Transportation Security Administration (TSA), the Department of Transportation (DOT), and members of both the House and Senate to pursue this reform. “The organ donation and transplant community rallied behind this cause, knowing that it represents major progress for our patients and selfless donors,” said Jerry McCauley, M.D., M.P.H., Immediate Past President of UNOS. “This change is also a cornerstone of the UNOS Action Agenda, a series of improvements we know will strengthen the U.S. donation and transplant system.” To further reduce risk of delay, damage or loss in organ transport, UNOS is recommending changes in the next contract for the Organ Procurement and Transplantation Network that would require the use of physical trackers for unaccompanied donor organs recovered for transplant, and the establishment of a centralized organ tracking system. The Senate Commerce Committee could mark up its reauthorization legislation as soon as next week. The Senate provision would require the FAA to establish regulations ensuring that donor organs transported via commercial flight can once again travel in the plane’s cabin, as opposed to traveling in cargo. “We look forward to supporting the passage of the provision in the Senate Commerce Committee and on the Senate floor,” said McBride. Sen. Maria Cantwell, Chair of the Senate Commerce Committee, Sen. Ron Wyden, Chair of the Senate Finance Committee, and Sen. Ted Cruz, Ranking Member of the Senate Commerce Committee, are supporters of the Senate provision. Actions to move organs back to the airplane cabin and out of cargo were widely endorsed by the donation and transplant community, including the American Association of Kidney Patients, American Foundation for Donation & Transplantation, American Society of Histocompatibility and Immunogenetics, American Society of Nephrology, American Society of Transplantation, American Society of Transplant Surgeons, Association of Organ Procurement Organizations, Donate Life America, Donate Life Virginia, Kidney Care Partners, Kidney Transplant Collaborative, National Kidney Foundation, Nationwide Organ Recovery Transport Alliance, North American Transplant Coordinators Organization, Organ Donation Advocacy Group, Renal Physicians Association, Transplant Recipients International Organization, Transplant Families, Transplant Unwrapped, and Waitlist Zero. Congress will need to advance reauthorization legislation before the current FAA authorization expires on September 30, 2023. About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

July 20, 2023 11:45 AM Eastern Daylight Time

Article thumbnail News Release

With ToolsGroup’s AI-Powered Planning, Legami Delivers Customer-Centric Service While Driving Business Growth

ToolsGroup

ToolsGroup, a global leader in supply chain and retail planning and optimization software, is thrilled to announce it has been selected by Legami, the Italian consumer goods company, to support its supply chain enhancement initiatives for heightened customer satisfaction and business performance through greater forecast accuracy and more nimble inventory management. Legami provides a wide array of products, including stationery, journals, calendars, greeting cards, personal care items, and travel and technology accessories. Its network encompasses a range of channels, including more than 40 brick-and-mortar boutiques, 17 shop-in-shops, an ecommerce site, and 10,000 authorized sellers and strategic partnerships with retail chains worldwide. Legami is proud to deliver more than 4,000 quality products to customers across 70 countries. To achieve a customer-centric supply chain, Legami searched for a planning solution that could reduce its network-wide inventory while maintaining and increasing service levels and business performance. This led to its selection of ToolsGroup Service Optimizer 99+ (SO99+). This automated, AI-powered solution includes Demand Planning & Forecasting and Inventory Optimization. With built-in probabilistic forecasting, it interprets demand signals for improved forecast accuracy, supporting demand-driven inventory planning and more granular control of stock levels. This minimizes inventory, reducing the environmental impact of production and transportation, and positions stock optimally to support both customer satisfaction and financial KPIs. “In today’s fluctuating market, competitive organizations are the ones achieving the optimal balance of resources that satisfies customer demand while propelling business growth," said ToolsGroup CEO, Inna Kuznetsova. “ToolGroup’s AI-driven dynamic planning delivers the demand-sensitive inventory management that helps companies identify and realize untapped business potential. We’re thrilled to partner with Legami to power better, faster planning decisions that lower working capital investments, widen margins, and guarantee a superior customer experience.” Learn more about how ToolsGroup’s solutions help consumer goods companies – like Melitta– increase forecast accuracy and profitability HERE. About Legami Legami (www.legami.com) is an Italian company active in the consumer goods industry, with a wide and varied offering that covers multiple sectors: Stationery, Diaries and Calendars, Greeting Cards, Lifestyle, Beauty, Hi-Tech, Travel and Accessories. With a strong emphasis on innovation, aesthetics, materials and production processes, the pillars of Legami’s corporate philosophy are passion, ethics, transparency, integrity, and respect for people and the environment. The creative soul and heart of Legami are in Italy, where all the products are designed and where the majority of the company’s 300+ employees work. Legami has a global network presence: more than 40 small boutiques owned in Italy, the eCommerce channel www.legami.com, 17 shops-in-shops, over 400 corners, 10,000 authorized sellers and strategic partnerships with the most important bookshops and chains in the world. About ToolsGroup ToolsGroup’s innovative AI-powered solutions enable retailers, distributors, and manufacturers to navigate through supply chain uncertainty. Our retail and supply chain planning suites empower a new level of intelligent decision making and unlock powerful business improvements in forecast accuracy, service levels, and inventory - delighting customers and achieving financial and ESG KPIs. Stay in touch with ToolsGroup on LinkedIn, Twitter, YouTube, or visit www.toolsgroup.com. Contact Details Meir Kahtan +1 917-864-0800 mkahtan@rcn.com Company Website https://www.toolsgroup.com

July 20, 2023 10:30 AM Eastern Daylight Time

Article thumbnail News Release

PathAI Launches AIM-HER2 Breast Cancer, an Artificial Intelligence-Powered HER2 Scoring Algorithm for Biopharma Research and Clinical Labs

PathAI

PathAI, a leading provider of AI-powered pathology tools to advance precision medicine, today announced the availability of AIM-HER2 Breast Cancer [i] for research use by clinical laboratories, researchers, and drug developers. AIM-HER2 Breast Cancer delivers automated digital HER2 scoring and is the market’s first algorithm to use additive multiple instance learning (aMIL) heatmaps to visualize the slide features driving the algorithm’s predicted score. AIM-HER2 will be available to biopharma researchers and clinical research lab pathologists on PathAI’s AISight TM [i] digital pathology platform in both the clinical research lab and clinical trial setting. “HER2 IHC assays have provided immense impact to patients by allowing for a widely available test to establish drug eligibility,” said Mike Montalto, Chief Scientific Officer at PathAI. “With AIM-HER2 Breast Cancer, we at PathAI sought to build upon the success of HER2 testing by assisting pathologists in their ability to more confidently score HER2, especially in borderline cases that can be the most challenging and time consuming to review. We also look forward to partnering with drug developers who may be interested in enhancing the scoring of the more recently described HER2 low assay as an important emerging patient population.” In addition to predicting slide-level HER2 score, AIM-HER2 Breast Cancer’s visualizations on AISight utilize additive multiple instance learning (aMIL) heatmaps to deliver a more interpretable and explainable prediction, diminishing the ‘black box’ challenges typically associated with understanding how AI predictions are made. “Our interpretable heatmaps are critical to driving utilization and adoption of AI – because it’s not about blind trust,” said Eric Walk, Chief Medical Officer at PathAI. “The results can be interpreted, explained – and confirmed – by humans. It also streamlines workflow as it allows pathologists to hone in on specific features to confirm the algorithm score and output vs. needing to analyze the entire slide.” AIM-HER2 Breast Cancer was developed using 157,000 tissue annotations and consensus scores on a dataset of over 4,000 slides (collected from more than 65 expert breast pathologists). In addition to slide-level HER2 scoring, AIM-HER2 Breast Cancer quantifies invasive carcinoma and provides a comprehensive analysis of the entire WSI without necessitating manual selection of the region of interest (ROI). To learn more about AIM-HER2 Breast Cancer, register for our webinar on Thursday, July 27, at 11:00am Eastern Time or visit www.PathAI.com Footnotes [i] Both AISight™ and the AIM-HER2 Breast Cancer Algorithm are intended for research-use only. Not for use in diagnostic procedures. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and diagnostic use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of patient samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to have a team of 600+ innovative thinkers from around the globe. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

July 20, 2023 10:00 AM Eastern Daylight Time

Article thumbnail News Release

UNOS Embraces Reform of the U.S. Donation and Transplant System

United Network for Organ Sharing

Ahead of today’s U.S. Senate Committee on Finance hearing on the nation’s organ donation and transplant system, United Network for Organ Sharing (UNOS) reiterates its commitment to modernizing and reforming the nation’s organ donation and transplant system and working with Congress to achieve measurable results for patients. UNOS is the mission driven non-profit that serves as the Organ Procurement and Transplantation Network (OPTN) under contract with the Health Resources & Services Administration (HRSA). “As long as there is a waitlist, it is our moral obligation to ensure we are promoting progress and increasing equitable access to lifesaving transplants,” said UNOS CEO Maureen McBride, Ph.D. “Patients and families are counting on us to pursue improvements that increase transparency, strengthen accountability, and save more lives. We support calls for patient-focused improvements and want to be part of the solution.” The UNOS Action Agenda After being appointed interim CEO in October 2022, McBride immediately began to work on a series of proposed changes that were announced in January 2023 as the UNOS Action Agenda. The Action Agenda drives UNOS’ continued advocacy efforts and outlines critical reforms in eight different areas. These areas include patient empowerment, equity, IT improvement, transportation, transparency, and governance. Many of these reforms have been endorsed by federal partners, members of Congress, and the wider organ donation and transplant community. Numerous components of the UNOS Action Agenda align with HRSA’s Modernization Initiative announced in March 2023. “We are committed to working with HRSA, the U.S. Department of Health and Human Services, Congress and others who care about this system so deeply to assist in carrying out these reforms and to do our part to improve how we serve America’s organ donors, transplant patients and their families,” said McBride. In support of a competitive bidding process, UNOS publicly announced in June that it does not oppose the Senate’s Securing the U.S. Organ Procurement and Transplantation Act, which would allow HRSA to increase competition for the management of the OPTN. Advancing Equity in Transplant UNOS’ Action Agenda includes calls to collect pre-waitlist data, an important change UNOS is advocating for with HRSA and Congress. Increases in transplant rates for minority patients are important and encouraging, but to eliminate inequities in access, more data is needed to understand and reduce inequities around which patients are added to the waiting list in the first place. “Equity in access to transplant begins well before a patient is added to the waitlist,” McBride says. “To address equity holistically, we also need to understand the barriers patients with end-stage organ failure face when it comes to being referred for transplant.” Maximizing The Gift Of Life While some Action Agenda proposals require collaboration with HRSA and the federal government, UNOS has advanced efforts to the extent of its authority since McBride became CEO. This includes work to improve the efficiency of the organ donation and transplant system. “Each organ donation represents a precious opportunity to save a life, and it is a tragic loss when a donor’s generosity does not result in another life saved,” said McBride. “We have been working on robust solutions to maximize the potential of donated organs by developing tools to make it easier for transplant hospitals to say ‘yes’ to an organ and by getting these organs to their destination more safely and quickly.” To address organ non-use – when an organ is recovered but not ultimately transplanted – UNOS and the OPTN have given transplant programs several tools to make it easier to say “yes” to an organ. At its June meeting, the OPTN Board of Directors approved the default use of offer filters for deceased donor kidney offers. These screening filters aim to speed up kidney acceptance rates and increase the number of transplants by sending time-sensitive organ offers automatically to programs most likely to accept organs with certain characteristics. Additionally, the OPTN recently launched a predictive analytics tool, and just concluded a national collaborative, aimed at improving organ acceptance rates at individual hospitals. To reduce the risk of delay and loss of organs traveling by commercial air, UNOS and the donation and transplant community advocated for and are supporting provisions in the next Federal Aviation Administration (FAA) reauthorization that would enable the transportation of a donated organ in the passenger cabin instead of in the cargo hold of an airplane. Because of a post-9/11 change, organs are currently transported as cargo, which does not operate around the clock like the lifesaving organ donation system does. Provisions in both the House and Senate FAA reauthorization bills could possibly reverse that long-standing practice. “As CEO of UNOS, I have sought a new level of collaboration and engagement with members of the nation’s organ donation and transplant community, our federal partners and elected officials,” said McBride. “UNOS is an organization that has not only embraced, but proposed, substantive reforms, and I look forward to working together to create a system that works better for every patient in need.” About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

July 20, 2023 09:30 AM Eastern Daylight Time

Article thumbnail News Release

DigiToads' TOADS up 370% as Ethereum Bulls Aim For This Key Price Level

Blockchain Digest

DigiToads (TOADS) is an interesting cryptocurrency that has experienced a parabolic rise to rank among the top-performing tokens in 2023. Emerging as a formidable contender to leading meme coins like Dogecoin (DOGE), its native token, TOADS, has experienced an exponential 370% surge in value, leaving investors scrambling to partake in the token. TOADS has undoubtedly become the talk of the town, captivating seasoned traders and newcomers. As bullish sentiment fills the crypto market, Ethereum's (ETH) ongoing bullish momentum has ignited speculation that its target is set at a key price level and could deliver higher prices. Ethereum has now caught the attention of enthusiasts and market participants alike with an impressive rally and the potential to rally to new highs. This article details the growth of TOADS and Ethereum's bullish target. Visit DigiToads Presale DigiToads' (TOADS) 370% Rally Confirms Its Potential To Deliver Exponential Returns Investors seeking to invest in the best ICO need not look any further than the incredible opportunity presented by the DigiToads presale. Savvy investors are already securing their spots aboard the DigiToads platform, fully aware that the value of the TOADS token is set to skyrocket after the upcoming tenth round of the presale. With the DigiToads presale approaching a thrilling climax, TOADS tokens are currently available for a mere $0.047 each. Considering its astonishing leap from the initial price of $0.01 during the first presale round, the cryptocurrency has delivered an impressive return of 370%. And there's more to come, as it is projected to max out at an additional 17% when it launches. Analysts have affirmed that DigiToads is the best crypto investment, with colossal profits awaiting investors after TOADS's upcoming decentralized exchange listing. On August 21st, 2023, TOADS will debut on two leading exchanges, Uniswap and BitMart, further increasing buying pressure and overall exposure. This could drive TOADS to reach milestone highs in the coming months. Both gamers and investors fixate on DigiToads as the best crypto investment. The reason for this keen interest lies in the fact that multiple industry giants have witnessed the innovation of DigiToads, and they confidently predict that its future growth will be nothing short of astronomical. The recent release of its NFT collection is a testament to DigiToads' potential, with multiple Web3 experts touting them as the best NFTs to invest in. Experienced investors are well aware of the impact that comes with the integration of in-demand technologies like the best NFTs to invest in and a highly anticipated play-to-earn game. They understand that prices can explode in a short time. Therefore, it is advisable to take advantage of this best ICO opportunity and acquire as many TOADS as possible before its subsequent price increase. Visit DigiToads Presale Ethereum (ETH) On The Climb Towards Higher Prices Ethereum has been bullish, breaking past the $2000 mark and reaching new heights. This impressive surge in price has been attributed to various factors, including the significant increase in on-chain activity and the overall bullish sentiment surrounding ETH. The unwavering support from prominent investors, known as whales, has further fueled the upward momentum of Ethereum. Despite experiencing a slight retracement after surpassing the $2000 resistance level, ETH remains optimistic in the eyes of analysts. Many experts predict that if the cryptocurrency can sustain its current level of whale activity and continue delivering positive developments, it has the potential to rally toward key price levels. They specifically anticipate Ethereum to target its previous yearly high of $2140 and even surpass it, potentially soaring to hit a new annual high of $2200 psychological level. Visit DigiToads Presale Conclusion As Ethereum continues to display bullish tendencies, the market's response to its recent performance has been encouraging, with traders eagerly anticipating its next move to key levels. Similarly, DigiToads' performance has been extraordinary in the crypto market. With an impressive 370% surge in value and a rapidly approaching listing on decentralized exchanges, TOADS could outperform crypto giants in the coming months. Join the DigiToads presale now and be part of one of the most significant crypto movements in 2023. Visit DigiToads Presale Mint DigiToads NFTs Here Buy DigiToads NFTs on OpenSea Join the community Contact Details Blockchain Digest Team noreply@blockchaindigest.net Company Website http://blockchaindigest.net

July 19, 2023 07:05 PM Eastern Daylight Time

Article thumbnail News Release

IQ-AI Limited shares latest progress from Phase I glioblastoma clinical trial

IQ-AI Ltd

Dr Jennifer Connelly, the Principal Investigator (PI) of the IQ-AI Limited sponsored Phase I Clinical Trial that is being conducted at the Medical College of Wisconsin, joins Proactive's Natalie Stoberman to discuss the latest updates from its treatment for recurring glioblastoma patients. IQ-AI Ltd, the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

July 19, 2023 01:03 PM Eastern Daylight Time

Video
1 ... 108109110111112 ... 311